1 To whom correspondence should be addressed deficient NMBA rat model is well-suited for investigation of Dietary zinc deficiency in rats induces hyperplasia in mechanisms involved in esophageal carcinogenesis because it the esophagus and increases N-nitrosomethylbenzylamine mimics aspects of the human cancer. In this regard, epidemiol-(NMBA)-induced esophageal tumor incidence. Previous ogical data have implicated dietary zinc deficiency (7-9) work showed a direct relationship between epithelial cell and exposure to carcinogenic N-nitrosamines and NMBA, in proliferation and esophageal tumor incidence in rats given particular, as possible causative factors of esophageal cancer multiple doses of NMBA. We investigated the effects of in high risk areas in northern China and parts of Iran (8,10-single low doses of NMBA in zinc-deficient rats since a single 12). Also, lesions induced by NMBA in the rat esophagus dose of 5.0 mg/kg was reported to be non-carcinogenic in are histologically similar to human esophageal cancers of rats. Zinc-sufficient and deficient rats received a single i.g.
squamous cell origin (13). dose of NMBA at 0.5 or 2.0 mg/kg. At week 14, tumor
Zinc deficiency per se produces proliferative changes in the incidence was 50% with 0.8 ⍨ 1.0 tumors/rat, and 80% rat esophagus including parakeratosis, hyperkeratosis and an with 2.2 ⍨ 1.9 tumors/rat, in deficient groups, D 0.5 and increase in the number of cell layers (14,15). Earlier, Schrager D 2.0 , that received the lower and higher dose, respectively. and his colleagues (16) noted that these changes pointed to a In addition, two small papillomas were found in one out relationship between zinc deficiency, cell replication and the of eight untreated zinc-deficient rats. None of the NMBAincidence of tumors. In recent years, evidence has been accumulating to support the hypothesis that cell proliferation treated or untreated zinc-sufficient rats had any tumors.
is an important mechanistic consideration for carcinogenesis Esophageal cell proliferation, as determined by proliferinduced by genotoxic and non-genotoxic agents (17-20), ating cell nuclear antigen (PCNA) immunohistochemistry, though others have expressed varying degree of scepticism showed that, irrespective of NMBA treatment, deficient (21-23). However, the consensus of opinions now appears to esophagi had significant increases in the number of labeled be that increased rate of cell proliferation is a risk factor for cells, the total number of cells, and the labeling index, as cancer (24-27). Very recently, work by our laboratory (3) compared with zinc-sufficient ones. Mutations in Ha-ras demonstrated a direct relationship between cell proliferation and p53 genes in esophageal tumors were detected by single and esophageal tumor incidence. Using the technique of in vivo strand conformation polymorphism (SSCP) analysis. DNA bromodeoxyuridine (BrDU) labeling of cells in S-phase of the sequencing of variant conformers revealed a point mutation cell cycle, we investigated the role of epithelial cell proliferation (GGA→GAA, codon 12) in Ha-ras in 4/5 (80%) and 5/8 throughout the development of esophageal cancer in zinc-(63%) tumors, from D 0.5 and D 2.0 rats, respectively. Three deficient and zinc-sufficient rats given six doses of NMBA at out of eight tumors from D 2.0 rats exhibited SSCP mobility 2 mg/kg, twice weekly over a period of 3 weeks. We found shifts within p53 exons 5 and 7: two tumors (2/8, 25%) that zinc-deficient rats that showed the most esophageal cell had missense mutations and the third, a silent mutation.
proliferation throughout the 14 week experimental period, had Of the two tumors with p53 mutations, one had a double the highest (100%) cancer incidence. In parallel, zinc-sufficient mutation (transition at codon 164, TCA→TTA; transverpair-fed rats, that demonstrated reduced esophageal cell prolifsion at codon 241, AGT→TGT), and the other tumor, a eration relative to the ad libitum fed group during the same transition at codon 172 (AGA→GGA), with amino acid period of time, had the lowest tumor incidence (3). These changes in all cases. In parallel with PCNA expression, results indicate the importance of sustained increased and elevated p53 expression was associated with hyperplastic reduced cell proliferation in esophageal carcinogenesis. and dysplastic regions, as well as with tumors, in deficient Recently, Siglin et al. (28) demonstrated that the duration esophagi. In short, these data indicate that dietary zinc of NMBA treatment is of critical importance in the tumorigenic deficiency, with its associated sustained increased cell prolifpotential of the carcinogen. They reported that a single subcutaeration in the esophagus, can drive an otherwise nonneous NMBA dose at 5.0 mg/kg was non-tumorigenic after 30 tumorigenic dose of NMBA into a highly tumorigenic one.
weeks in rats fed a nutritionally complete AIN-76A diet, and NMBA regimens of 2 weeks or less were also essentially ineffective. Their results suggest that the tumorigenicity of for 50 s; annealing at 54°C for exon 5, 55°C for exon 6, 61°C for exons 7 with a 12 h light-dark cycle. They were given free access to deionized and 8 for 50 s; extension at 72°C for 70 s; and a final 7 min extension step drinking water and were randomized into two dietary groups: half of the after the last cycle. Primer sequences for exon 1 of the Ha-ras gene have animals were fed a zinc-deficient diet ad libitum and the other half, a zincbeen described (30) and annealing temperature was 57°C. sufficient diet ad libitum. All rats were weighed weekly. After 5 weeks, the SSCP analysis animals received either no treatment or a single intragastric dose of NMBA at 0.5 or 2.0 mg/kg in saline. They then continued on their respective diets.
PCR-amplified products of the p53 gene (exons 5-8) and Ha-ras gene (exon After 14 weeks, all animals were killed by isoflurane (Ohmeda Inc., NJ) 1) were screened for mutations using radioactive SSCP analysis according to inhalation following the collection of blood from the retro-orbital plexus of the procedure described by Orita et al. (38) . Briefly, PCR products were each rat for serum zinc level determination (3). Whole esophagi were removed, diluted 10-fold with a loading buffer consisting of 95% formamide, 20 mM mapped for tumor incidence, and processed for immunohistochemical studies, EDTA, 0.05% bromophenol blue and 0.05% xylene cyanol. The mixture was and DNA isolation for single-strand conformation polymorphism (SSCP)-heated at 97°C for 10 min and immediately chilled on ice. The denatured polymerase chain reaction (PCR) analysis as described below.
mixture was then subjected to electrophoresis using a 0.5ϫ Tris-borate-EDTA (TBE) running buffer in a DNA-sequencing system (Fisher Biotech, Tumor studies Pittsburgh, PA). Two electrophoretic conditions were used for the p53 gene: At autopsy, whole esophagi were removed carefully, opened lengthwise and (i) a 8% polyacrylamide gel (Acrylamide/Bis, 39:1) was run at 30 W in a examined. Esophageal tumors with diameters Ͼ0.5 mm were mapped and cold room for 3.5 h; and (ii) a 5% glycerol-containing gel was run at 2 W at counted. The esophagi were then fixed in methacarn (methanol: room temperature for 17 h. To screen mutations in exon 1 of the Ha-ras gene, chloroform:glacial acetic acid, 6:3:1) and embedded in paraffin. Serial cross a 15% polyacrylamide gel (Acrylamide/Bis, 99:1) with 10% glycerol was run sections (4 µm) were prepared and were either stained with hematoxylin and at 2 W at room temperature for 18.5 h. The gels were then dried on filter eosin (H&E) for histopathology or left unstained for immunohistochemical paper and subjected to autoradiography against an X-ray film (Kodak, Xassays.
OMAT AR film).
Immunohistochemistry
Amplified PCR products of exons 5-8 of the p53 gene were also screened for mutations using a non-radioactive SSCP method according to the procedures For PCNA staining, tissue sections were deparaffinized, and rehydrated in graded alcohol. Endogenous peroxidase was inhibited with hydrogen peroxide described by Hongyo et al. (39) . Two temperature-controlled vertical gel systems were used: (i) a Hoefer vertical gel apparatus (model SE 600, and non-specific binding sites were blocked with normal goat serum. Slides were incubated overnight at room temperature with primary antibody, monoPharmacia Biotech Inc., San Francisco, CA) with a 10% polyacrylamide gel (14.5 cmϫ14.5 cmϫ0.75 mm, 15-well), made from 40% electrophoresis clonal mouse anti-PCNA (Santa Cruz Biotechnology, Santa Cruz, CA) at 1:400 dilution, followed by incubations with biotinylated goat anti-mouse matrix (PAGE-Plus Concentrate, Amresco, Solon, OH), glycerol (2-4%) and 1ϫ TBE (40) ; and (ii) a Novex Electrophoresis Temperature Control unit (39) antibody and then with strepavidin horseradish peroxidase. PCNA was localized by a final incubation with 3-amino-9-ethylcarbazole (AEC)-substratewith a 20% pre-cast TBE polyacrylamide gel (8 cmϫ8 cmϫ1.0 mm, 10-well, Novex, San Diego, CA). Both units were used in connection with a Lauda chromogen system (Dako Corp., Carpinteria, CA). Cells with red reaction product in the nucleus or cytoplasm were considered positive for the presence Refrigerating Circulator (model RM6, Brinkmann Instruments, Westbury, NY) which provided a precise and constant (Ϯ0.02°C) temperature control for of PCNA. In the scoring of labeled cells, the basal epithelial cells of the cross section of an entire esophagus were counted by light microscopy. Labeling electrophoresis. Before electrophoresis, PCR products were purified by a PCR purification kit (Qiagen, Chatsworth, CA) and their OD 260 determined. About index (LI) was calculated by dividing the number of labeled cells by the total number of cells, and the result was expressed as a percentage.
2 ng of PCR product was mixed with 0.32 µl of 1 M methylmercury hydroxide (Johnson Mattey Electronics Inc., War Hill, MA), 0.5 µl loading buffer (15% For p53 protein(s) (wild and mutant) staining, tissue sections were heated in a target unmasking fluid (Signet Lab., Dedham, MA) in a microwave oven Ficoll 400, 6 mM EDTA, 0.05% Bromophenol Blue and 0.05% xylene cyanol) and 1ϫ TBE to a final volume of 12 µl. The mixture was then denatured by for 5 min to expose the antigens prior to blocking with normal goat serum. Sections were then incubated overnight at room temperature with primary heating at 85°C for 5 min and chilled on ice before it was loaded onto the gel. In the Hoefer unit, the gel was run at 500 V at a constant temperature of antibody CM-1 (Signet Lab.) at 1:25 dilution, followed by incubation with biotinylated goat anti-rabbit antibody (Dako Corp.). p53 expression was 1.5ϫ TBE buffer for~4-5 h. Optimal temperatures for various exons were determined by experiments: 21°C for exons 5 and 8; 16°C for exons 6 and 7. visualized by a final incubation with 3,3-diaminobenzidine-substrate chrom- In the Novex unit, the gel was run at 300 V at a constant temperature of 1.5ϫ TBE buffer: 8°C for exons 5 and 8; 16°C for exons 6 and 7. DNA was Table I shows that a single dose of NMBA, at 0.5 or 2.0 mg/ kg was ineffective in inducing esophageal tumors in zincsufficient rats, S 0.5 and S 2.0, at week 14 post-carcinogen treatfor the group; and (iii) the percentage of labeled cells or labeling index per cross-section of an esophagus, averaged for ment, but produced 50% and 80% tumor incidence, respectively, in similarly-treated zinc-deficient animals, D 0.5 and D 2.0 . the group. The data in Table II demonstrate that independent of NMBA treatment, zinc-deficient groups (D 0 , D 0.5 or D 2.0 ) The difference in tumor incidence between zinc-deficient and sufficient groups was significant at P Ͻ 0.03 for D 0.5 versus had significantly higher (i) number of labeled cells, (ii) total number of cells, and (iii) labeling index, than the respective S 0.5 , and P Ͻ 0.004 for D 2.0 versus S 2.0 . Tumor multiplicity and size were greater in the higher dose group: D 2.0 rats had zinc-sufficient group (S 0 , S 0.5 or S 2.0 ). The differences: D 0 versus S 0 , D 0.5 versus S 0.5 , and D 2.0 versus S 2.0 , were significant 2.2 Ϯ 1.9 tumors/rat, and D 0.5 animals, 0.8 Ϯ 1.0. These tumors were mostly exophytic papillomas, and occurred more freat P Ͻ 0.001 for each of the three indicators of epithelial cell proliferation studied. NMBA treatment had no apparent effect quently in the upper two-thirds of the esophagus. Interestingly, two small papillomas were found in one of eight (12.5%) on esophageal cell proliferation in zinc-deficient groups. However, in zinc-sufficient groups, S 2.0 rats that had received a NMBA-untreated, zinc-deficient rats. These results confirmed our previous observation that sustained increased esophageal single dose of NMBA at 2 mg/kg, had a significantly higher number of labeled cells (P Ͻ 0.01) and labeling index (P Ͻ cell proliferation can elicit a tumorigenic response in the absence of a carcinogenic insult (3). 0.01) than untreated counterparts (S 0 ), 14 weeks post-treatment. Figure 1a shows that, typically, in esophageal epithelia from Table II to the nuclei of the basal, and in some cases, immediately suprabasal layer of the epithelium. By contrast, a dramatic per cross-section of an esophagus averaged statistically for the group; (ii) the total number of cells, both labeled and unlabeled, increase in PCNA immunoreactivity was seen in epithelia from zinc-deficient animals (D 0 , D 0.5 or D 2.0 ), and was identified in the nuclei of many cell layers, often in association with hyperplasia and dysplasia (Figure 1b) . PCNA immunoreactivity was also detected in the nuclei of tumor cells from zincdeficient rats (Figure 1c) . In this regard, expression of p53, as detected by antibody CM-1, followed a spatial and temporal pattern similar to that of PCNA. Thus, in zinc-sufficient rats, p53 expression was found to be mostly restricted to the nuclei of the basal, and immediately suprabasal layer of the epithelium (Figure 2a) , and was greatly increased in zinc-deficient rat esophagi, showing hyperplasia and dysplasia (Figure 2b) , and in esophageal tumors (Figure 2c) .
Expression of PCNA and p53 in zinc-deficient rat esophageal Esophageal cell proliferation as determined by quantitative PCNA immunohistochemistry epithelium

Ha-ras mutation in zinc-deficient rat esophageal papillomas
Ha-ras gene exon 1 mutations were screened for by radioactive SSCP analysis in esophageal tissue, and tumors isolated from all experimental animals at week 14. Mobility shifts were seen only in the amplified PCR products derived from tumors. DNA sequence analysis revealed a mutation at the 35th nucleotide in the Ha-ras coding sequence, involving a guanine to adenine transition (GGA→GAA, codon 12), thus leading to an amino acid change from glycine to glutamate. The incidence of mutation was 80% (4/5 tumors), and 63% (5/8 tumors), for D 0.5 and D 2.0 groups, respectively. Figure 3 illustrates an example of radioactive SSCP and DNA sequence analyses of this exon.
p53 gene mutations in zinc-deficient rat esophageal papillomas
Mutations in exons 5-8 of the p53 gene were screened for by both radioactive and non-radioactive SSCP analyses in esophageal tissue and tumors obtained from all animals at week 14. Our results indicate that the two methods were comparable in their sensitivity to detect mutations. In addition, resolution of bands, using either the Novex or Hoeffer system, was comparable. Mobility shifts were seen only in tumor samples from D 2.0 rats, and not in any of the five tumor samples from D 0.5 rats. Amplified products from three out of eight tumors (T6, T8 and T10) from D 2.0 rats, exhibited mobility shifts for exons 5 and 7, as illustrated in Figure 4 for exon 5. Sample T6 showed mobility shifts in both exons (results not shown). DNA sequencing analysis ( Figure 5 ) revealed two mutations in T6: a transitional mutation (TCA→TTA, codon 164), and a tranversional mutation (AGT→TGT, codon 241), resulting in amino acid substitutions of serine in both cases. It is possible that the double mutation detected may have derived from two fused multifocal papillomas (32), despite the fact that p53 mutation analysis was performed on individual tumors. Sample T8 showed a mobility shift in exon 5 (Figure 4 ), due to a transitional mutation in codon 172 (AGA→GGA), resulting in arginine substitution ( Figure 5 ). However, for sample T10, the mobility shift for exon 5 (Figure 4) , was because of a silent mutation (GTC→GTT, codon 155), which resulted in no amino acid change ( Figure 5) . Thus, the prevalence of p53 mutations in D 2.0 tumors was 25% (2/8). In addition, tumor samples T6 and T8 contained both Ha-ras and p53 mutations. zinc deficiency, an otherwise non-tumorigenic dose of NMBA (examined after 14 weeks) becomes highly tumorigenic in the rat esophagus (Table I) . It is noteworthy that the single NMBA Cold SSCP was done in a Novex apparatus with a pre-cast 20% polyacrylamide TBE gel; circulating buffer temperature was 8°C. The gel was stained by a silver staining kit. Lane 1, molecular weight marker (Hae III digest of φX174 DNA). Lane 2, an esophageal tissue sample from an untreated zincsufficient rat. Lane 3, 'positive' control*. Lanes 4-7, tumor samples from four D 2.0 rats in the sample order: T8, T10, T4 and T5. Mobility shifts are seen in lanes 3, 4 and 5 (positive control, T8 and T10 respectively). *Positive control ϭ an esophageal tumor sample from a zinc-deficient rat that had received multiple doses of NMBA from an earlier study, in which case, DNA sequencing analysis reveals a mutation in codon 145 (CTG→CTA) of p53 exon 5 (unpublished results). T, tumor tissue.
dosages (0.5 and 2.0 mg/kg) used in the present study, are substantially lower than the reported non-tumorigenic single NMBA dose of 5 mg/kg or the essentially non-tumorigenic, cumulative dosages of 7.5 or 10.0 mg/kg, given over the course of 1-2 weeks, in nutritionally-complete rats (28). In addition, consistent with our previous observation (3), one out of eight NMBA-untreated, zinc-deficient animals developed two small esophageal papillomas (Table I) ; these findings lend support ation of NMBA (42-44) by rat esophageal cytochrome p450 isozymes to benzaldehyde and a methylating species, which preferentially methylates DNA at the O 6 -, and N7-positions der cancer model, is greatly influenced by the effect of 2-AAF on cell proliferation. Also, Van Benthem et al. (55) have shown that 72 h after the administration of multiple doses of NMBA to rats, accumulation of O 6 -meG is restricted to tissues that have low levels of cellular proliferation relative to the esophagus, and for which tumor induction by NMBA has not been reported. These authors concluded that the tumorigenic organotropism of NMBA is determined both by the level of DNA methylation and the proliferative capacity of the methylated cells. The enhanced NMBA carcinogenicity observed in zincdeficient rats (1-6) is probably brought about by a combination of (i) increased esophageal microsomal metabolism of NMBA (56); (ii) increased formation of O 6 -meG (57); (iii) depressed esophageal activities of the repair enzyme, O 6 -alkylguanine-DNA-methyltransferase (58); and (iv) sustained increased esophageal cell proliferation. The results from our studies (3, and the present study) indicate that sustained increased epithelial proliferation is probably, by a wide margin, the most important factor in substantially increasing the effectiveness of NMBA in tumor induction, because increased cell proliferation might contribute to increased cancer risk, among other effects, via decreasing the time available for DNA repair and thus fixing the errors (3,17,18).
Studies in human populations at high risk for esophageal cancer have shown that epithelial hyperplasia and dysplasia are early indicators for the disease (59-61). Wang et al. (62) reported that during human esophageal cancer development, by the cells that stained positively for p53. These authors reported that~75% of the samples with normal esophageal epithelia were positive for p53. Interestingly, the same sequence of guanine (45, 46) . O 6 -Methylguanine (O 6 -meG), the major promutagenic DNA adduct (47, 48) , is associated with base of events for the expression of p53 and PCNA is found in our zinc-deficient NMBA rat model: expression of p53, as detected mispairing and mutagenesis (47, 49) and with a G:C→A:T transition in the lac 1 gene and gpt gene (50, 51) . The formation by CM-1 (Figure 2a , b and c), followed a spatial and temporal pattern similar to that of PCNA ( Figure 1a , b and c), and and persistence of O 6 -alkylguanine is considered to be of major importance in the initiation of tumors (52,53). NMBAincreased as the esophageal epithelium progressed from normal to hyperplasia, dysplasia, and finally to tumor formation. induced rat esophageal tumors exhibit frequent mutations in the Ha-ras oncogene, and the p53 tumor suppressor gene.
Thus in both human and rat esophageal carcinogenesis, the overexpression of p53 could be an early and common event Consistent with the mode of action of O 6 -meG, Ha-ras mutations in these tumors invariably involve a G→A transition in esophageal carcinogenesis. The p53 protein is now established as a key negative in codon 12 (29) (30) (31) , whereas mutations in p53 are often G:C→A:T transitions in exons 5 through to 8, with no apparent regulator of cell proliferation (63,64 for citations of references), and its inactivation, either by point mutation or other mechanhot-spot codons (31, 32) .
In agreement with our previous study (3), there is a strong isms such as DNA damage, appears to be essential for the progression of most tumor types. The molecular basis of correlation between epithelial cell proliferation, as measured by quantitative PCNA immunohistochemistry (Table II) , and p53 accumulation, observed in the highly proliferative zincdeficient esophageal epithelium, and in the progression of the esophageal tumor incidence. Zinc-deficient groups have significantly higher numbers of labeled cells, total numbers of cells pre-cancerous lesions in human esophageal carcinogenesis (62) , is not known. The event that causes p53 stabilization and labeling indices, than respective zinc-sufficient groups. NMBA treatment did not further increase cell proliferation in leading to its accumulation is of major importance in the improved treatment of cancer, its diagnosis and prevention (64) . deficient rats but produced a slight increase in the tumor-free zinc-sufficient rats, which received 2.0 mg/kg NMBA; these Thus, to understand the relationship between the occurrence and over-expression of p53 and cell proliferation in the zinclatter results are in line with those of Siglin et al. (28) . Together, our data suggest (i) epithelial cell proliferation must deficient NMBA rat model, will be helpful. Our findings, that 80% of D 0.5 papillomas (4/5) and 63% of be substantially increased for tumor development to occur; and (ii) DNA modification, an important factor in carcinogenesis, is D 2.0 papillomas (5/8) have G 35 →A mutation in the Ha-ras gene, are comparable to the 67% frequency in esophageal not sufficient to lead to tumor induction. In support of our argument, Cohen and Ellwein (54) earlier observed that tumor papillomas from nutritionally-complete rats receiving a total of 17 doses of NMBA (2 mg/kg, twice weekly) reported by prevalence in the 2-acetylaminofluorene (2-AAF)-mouse blad-NMBA, is different from that seen in esophageal tumors genesis in zinc-deficient rats: effects on incorporation of [ 3 H]thymidine into induced by multiple doses of NMBA in nutritionally-complete DNA of esophageal epithelium and liver. Carcinogenesis, 7, 1121-1126. rats (31, 32) . These data, which show p53 mutational transitions In conclusion, our data suggest that sustained increased cell 
